Kezar Life Sciences, Inc.

NasdaqCM KZR

Kezar Life Sciences, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Kezar Life Sciences, Inc. Operating Income Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Kezar Life Sciences, Inc. Operating Income Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -1,383.84%.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

NasdaqCM: KZR

Kezar Life Sciences, Inc.

CEO	Dr. Christopher J. Kirk Ph.D.
IPO Date	June 21, 2018
Location	United States
Headquarters	4000 Shoreline Court
Employees	58
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.

Key trends

Past 5 years